Global Viral Vector Production Market to grow with a CAGR of 14.21% through 2028
Rising Prevalence of Genetic Disorders and initiatives
taken by the government are the major drivers for the Global Viral Vector
Production Market.
According to TechSci Research report, “Global
Viral Vector Production Market Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Viral Vector
Production Market stood at USD 5.22 billion in 2022 and is anticipated to
project robust growth in the forecast period with a CAGR of 14.21% through
2028. The Global Viral Vector Production Market is anticipated
to register a high CAGR during the forecast period. This can be ascribed to
collaborations and partnerships among leading companies with a diverse approach
to merge the expertise of individual companies and to strengthen their position
in the market.
Viral vectors (or ‘carriers’) are tools used to
transfer genetic material to cells. Viable viruses have specialized mechanisms
that transport their genome into the target cells they infect. In gene therapy,
modified viruses (also known as viral vectors) are used as carriers to protect
the new gene from damage while delivering it into the ‘gene cassette’ in target
cells. Viral
vectors induce target cells to assimilate and separate the novel gene from the
viral particle and, for example, to transport the new gene into the cell
nucleus. Target cells then begin to utilize the novel gene to carry out its
function. Due to genetic engineering, most of the necessary genes are missing
in viral vectors. As a result, viral vectors are typically cultivated in
culture with specialized cells that supply the missing viral protein necessary
to successfully assemble the therapeutic gene or gene pair into virus
particles. The coronavirus pandemic has highlighted the need for vaccine
development to meet the needs of the global population and has positively
impacted the development and expansion of the global market for viral vector
manufacturing.
At least 17 vaccines are currently in use according to the World
Health Organization (WHO) Global COVID - Strategic Vision 2022. The global market
for viral vector production has been significantly impacted by the rise in the
incidence of cancer, infectious disease, and genetic disorders. The prevalence
of these diseases has led to an increase in the burden of innovative therapies,
such as gene therapy. As the incidence of these diseases increases, so has the
need for viral vectors to facilitate the development and production of gene
therapies.
Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " Global Viral Vector Production Market”
This has contributed to the expansion of the market size for viral
vector production. 12,88 billion doses have been administered as of 8
November 2022, and 400+ vaccine candidates are in clinical or preclinical
development, and two viral vector vaccines are approved for emergency use for
COVID in many countries as of 7 January 2022, as published in the Viral vector
vaccines segment of the Infectious disease’s society of America. To overcome the
supply shortage in space, several manufacturers have invested heavily to expand
their production capacities. For example, on February 12th, 2021, Vigo
Bioscience entered a contract for a 50.0% increase in viral vector capacity at
a new facility located in Maryland. Additionally, Viblogics initiated the first
phase of its USD 150 million capacity expansion project.
These investments are
expected to drive the expansion of the research-use viral vector production
market in the years to come. Additionally, several companies are introducing their products
and engaging in a range of partnerships, collaborations and other developments
that are anticipated to have a positive effect on the market. For example, in
April 2020 AstraZeneca announced a collaboration with Oxford University to
develop a virus-vectored vaccine using a modified, replication-deficient Chimp
Adenovirus vector (ChAdOx1). For instance, a viral vector vaccine has been
developed by Johnson & Johnson’s (J&J) Janssen biotech (Janssen
Biotech) using a replication incompetent human Adenovirus vector. The vaccine
was approved by the US Food and Drug Administration (FDA) in February 2021.
Viral vector manufacturing is becoming increasingly important in research and
development. Furthermore, since the recombinant virus vectors are highly efficient
transmitters of sequences coding for virus-eliminating sequences, it is
typically necessary to select and modify the appropriate and precise viral
vectors for use in the management of viral infections. At present, there are
several public and private-sector initiatives underway to develop viral vector
vaccines. The market for viral vector production is expected to experience a
significant expansion in the future due to the growing pipeline of gene
therapies and viral vaccines. As viral vectors are essential for the delivery
and effectiveness of these therapies, the demand for them is expected to
increase as the pipeline continues to expand in various therapeutic fields.
However, Human Capital
and Expertise and Intellectual Property and Licensing are expected to slow down
the growth of the market in the coming years.
The Global Viral Vector
Production Market segmentation is based on Vector Type, Workflow, Application,
End User, By Company, and Region.
Some of the major companies
operating in the United
Global Viral Vector Production Market include:
- Merck kgaa
- Lonza
- FUJIFILM Diosynth Biotechnologies U.S.A
- Cobra Biologics Ltd.
- Thermofisher Scientific Inc.
- Waisman Biomanufacturing
- Genezen Laboratories
- YPOSKESI
- Advanced BioScience Laboratories, Inc. (ABL inc.)
- Novasep Holding s.a.s.
- Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
- Takara Bio Inc.
- RegenxBio, Inc.
- Aldevron LLc.
- Bluebird Bio Inc.
Download Free Sample Report
Customers can also request for 10% free customization on this report.
“Certain areas, particularly in the Northeast, are projected
to exert significant demand for Viral Vector globally. The growth in the
competitive landscape and the presence of well-established companies in the
market, committed to enhance the overall wellbeing of people each year, are
expected to contribute to a remarkable growth of the Global Viral Vector
Production Market in the forecast period," said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based Global management consulting
firm.
Viral Vector Production
- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028
Segmented By Vector Type (Adenovirus, AAV, Lentivirus, Retrovirus, others), By
Workflow (Upstream Processing, Vector amplification and expansion, Vector recovery/harvesting,
Downstream Processing, Purification,
Fill finish), By Application (Gene and Cell Therapy Development, Vaccine
Development, Biopharmaceutical and Pharmaceutical Discovery, Biomedical Research), By End User
(Pharmaceutical and Biopharmaceutical Companies, Research Institutes), By
Region, Competition has
evaluated the future growth potential of Global Viral Vector Production Market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide innovative market intelligence and
help decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Viral Vector Production Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web: https://www.techsciresearch.com